Halozyme Therapeutics reported $-0.24 in EPS Earnings Per Share for its fiscal quarter ending in December of 2025.


Fiscal Calendar Actual Consensus Previous Date
FY2025Q4 Dec/2025 -0.24 1.9 1.26 Feb/17 2026
FY2025Q3 Sep/2025 1.72 1.59 1.27 Nov/03 2025
FY2025Q2 Jun/2025 1.54 1.21 0.91 Aug/05 2025
FY2025Q1 Mar/2025 1.11 0.96 0.79 May/06 2025
FY2024Q4 Dec/2024 1.26 1.15 0.82 Feb/18 2025




Eps Change Date
Acadia Pharmaceuticals USD 1.6 1.18 Dec/2025
Agios Pharmaceuticals USD -1.86 0.08 Dec/2025
Alnylam Pharmaceuticals USD 1.25 1.65 Dec/2025
Amarin USD 0.08 0.11 Sep/2025
Amgen USD 5.29 0.35 Dec/2025
Baxter International USD 0.44 0.25 Dec/2025
Cara Therapeutics USD -5.04 3.24 Dec/2024
Cytokinetics USD -1.5 1.05 Dec/2025
DBV Technologies USD -0.24 1.31 Sep/2025
Eli Lilly USD 7.54 0.52 Dec/2025
Esperion Therapeutics USD -0.15 0.18 Sep/2024
Halozyme Therapeutics USD -0.24 1.96 Dec/2025
Intrexon USD -0.1 0.03 Jun/2024
Ionis Pharmaceuticals USD -1.41 0.61 Dec/2025
MannKind USD 0.01 0.06 Dec/2025
Minerva Neurosciences USD -0.56 3.53 Dec/2024
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pfizer USD 0.66 0.21 Dec/2025
Rigel Pharmaceuticals USD 0.7 0.76 Sep/2024
United Therapeutics USD 7.7 0.54 Dec/2025
Vanda Pharmaceuticals USD -0.09 0 Dec/2024